<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="60263">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02321436</url>
  </required_header>
  <id_info>
    <org_study_id>Y-79-52120-197</org_study_id>
    <nct_id>NCT02321436</nct_id>
  </id_info>
  <brief_title>Study to Assess Impact of Dysport Injections Early After Stroke on Upper Limb Spasticity Progression</brief_title>
  <acronym>ONTIME Pilot</acronym>
  <official_title>Asian Multicentre, Double Blind, Randomised, Placebo Controlled Pilot Study, to Assess the Impact of Dysport® Intramuscular Injections When Administered Within the First 12 Weeks After Stroke on the Time to Spasticity Progression in Adult Subjects With Upper Limb Spasticity.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Ipsen</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Ipsen</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to investigate if early administration (i.e. within 12 weeks
      after stroke) of Dysport® 500 U injections may delay the appearance of the progression of
      upper limb symptomatic spasticity.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>December 2014</start_date>
  <completion_date type="Actual">March 2016</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Double Blind (Participant, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Time between the initial injection and reinjection criteria occurrence</measure>
    <time_frame>Week 4 and up to 28 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in muscle tone using Modified Ashworth Scale (MAS)</measure>
    <time_frame>Week 4 and every 4 weeks up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Median time from initial injection to re-injection visit</measure>
    <time_frame>Week 4 and every 4 weeks up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change in Fugl-Meyer Assessment (FMA) from initial injection visit to re-injection visit</measure>
    <time_frame>Week 4 and every 4 weeks up to 28 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Global assessment of changes assessed by the investigator</measure>
    <time_frame>Week 4 and up to 28 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">42</enrollment>
  <condition>Stroke</condition>
  <condition>Upper Limb Spasticity</condition>
  <arm_group>
    <arm_group_label>Treatment group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Dysport® 500U intramuscular injection</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo Group</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo intramuscular injection</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BotulinumtoxinA</intervention_name>
    <description>Subjects to receive Dysport® 500U administered intramuscularly in the targeted upper limb.</description>
    <arm_group_label>Treatment group</arm_group_label>
    <other_name>Dysport®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo administered intramuscularly in the targeted upper limb.</description>
    <arm_group_label>Placebo Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  2 to 12 weeks after first ever stroke according to the World Health Organisation
             criteria (previous transient ischaemic attack or clinically silent infarct on
             computerised tomography (CT)/magnetic resonance imaging (MRI) are not counted as
             previous stroke)

          -  Stroke confirmed by CT/MRI scan and classified as ischaemic/haemorrhagic stroke

          -  Presence of spasticity, either symptomatic, based on symptomatic spasticity criteria
             (i.e. at least one of the following items: impacted passive/active function,
             involuntary movements and pain ≥4 on a numeric pain rating scale [NPRS]) or not
             symptomatic in the relevant upper limb

        Exclusion Criteria:

          -  Neuromuscular junction (NMJ) diseases, or any other neurological disorders (including
             prior local joint, tendon, and intrinsic muscle disorders) that could potentially
             interfere with assessment of spasticity in the primary targeted muscle group selected
             by the Investigator and in agreement with the subject

          -  Currently receiving drugs affecting NMJ transmission e.g. aminoglycosides,
             aminoquinolines, cyclosporine, D penicillamine

          -  Previous surgery of the affected muscles/ ligaments/tendons

          -  Severe comorbidities (e.g. congestive heart failure, myocardial infarction, multiple
             organ failure, hepatic renal failures, severe infections)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jovita Balcaitiene, MD</last_name>
    <role>Study Director</role>
    <affiliation>Ipsen</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Neurology Laboratory -University Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <zip>59100</zip>
        <country>Malaysia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Neurodiagnostic and Therapeutic Services Metropolitan Medical Center</name>
      <address>
        <city>Manila</city>
        <zip>1003</zip>
        <country>Philippines</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>TTSH Rehabilitation Centre Ang Mo Kio Community Hospital</name>
      <address>
        <city>Singapore</city>
        <zip>569766</zip>
        <country>Singapore</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Department of rehabilitation Medicine Faculty of medicine Siriraj Hospital, Madihol University Hospital</name>
      <address>
        <city>Bangkok</city>
        <zip>10700</zip>
        <country>Thailand</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Malaysia</country>
    <country>Philippines</country>
    <country>Singapore</country>
    <country>Thailand</country>
  </location_countries>
  <verification_date>April 2016</verification_date>
  <lastchanged_date>April 21, 2016</lastchanged_date>
  <firstreceived_date>December 17, 2014</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Stroke</mesh_term>
    <mesh_term>Muscle Spasticity</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>abobotulinumtoxinA</mesh_term>
    <mesh_term>Botulinum Toxins, Type A</mesh_term>
    <mesh_term>onabotulinumtoxinA</mesh_term>
    <mesh_term>incobotulinumtoxinA</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
